207_Combined course Presentations

Basket trials matching patients to therapies based on molecular profiles

Primary outcome measure(s)

Clinicaltrials. gov identifier

Program name

Lead organization

# Expected to accrue

Design Histology Indication

ALK or ROS1 mutated solid tumors and/or hematologic malignancies Solid tumors and/or hematologic malignancies with aberrations in FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk, or RET

SIGNATURE

Novartis

NR

Metastatic

70

CBR

NCT02186821

Metastatic

80

CBR

NCT01831726